PMID- 12096391
OWN - NLM
STAT- MEDLINE
DCOM- 20020920
LR  - 20131121
IS  - 0016-3813 (Print)
IS  - 0016-3813 (Linking)
VI  - 138
IP  - 3
DP  - 2002 May-Jun
TI  - [Peripheral blood hematopoietic cell transplant using immunosuppressive 
      chemotherapy without bone marrow destruction: "minitransplant"].
PG  - 235-9
AB  - Using a nonmyeloablative, immunosuppressive, fludarabine (FLU)-base conditioning 
      regimen, we have performed allogeneic peripheral blood stem cell transplants in 
      17 patients (six with chronic granulocytic leukemia, four with acute myelogenous 
      leukemia, five with acute lymphoblastic leukemia, one with myelodysplasia and 
      one, with thalassemia major). Conditioning regimen consisted of 
      FLU/busulfan/cyclophosphamide or FLU melphalan. To avoid graft vs. host disease 
      (GVHD), cyclosporine and methotrexate were used. Median granulocyte recovery time 
      to 0.5 x 10(9) was 11 days, whereas median platelet recovery time to 20 x 10(9) 
      was 12 days. Seven patients did not need red blood cell transfusions and four did 
      not need platelet transfusions. In thirteen individuals (76%), the procedure 
      could be completed fully on an outpatient basis. Follow-up times range between 1 
      and 14 months. Five of 17 patients developed acute GVHD whereas 4/10 developed 
      chronic GVHD. The 14-month survival (SV) is 70% and median SV is not reached. 
      Five patients (29%) have died, three due to relapse of the disease and two due to 
      GVHD. The transplant-related mortality was 5.8%. This procedure is substantially 
      less costly than its counterpart, using in-hospital myeloablative conditioning 
      regimens, and may represent another approach in management of patients requiring 
      allogeneic stem cell transplant.
FAU - Gomez-Almaguer, David
AU  - Gomez-Almaguer D
AD  - Servicio de Hematologia, Hospital Universitario de la UANL. 
      dr_gomez@infosel.net.mx
FAU - Ruiz-Arguelles, Guillermo J
AU  - Ruiz-Arguelles GJ
FAU - Gonzalez-Llano, Oscar
AU  - Gonzalez-Llano O
FAU - Ruiz-Arguelles, Alejandro
AU  - Ruiz-Arguelles A
FAU - Cantu-Rodriguez, Olga G
AU  - Cantu-Rodriguez OG
LA  - spa
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Trasplante de celulas hematopoyeticas de sangre periferica utilizando 
      quimioterapia inmunosupresora sin destruccion de la medula osea: 
      "minitrasplante".
PL  - Mexico
TA  - Gac Med Mex
JT  - Gaceta medica de Mexico
JID - 0010333
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (Cyclosporins)
RN  - 0 (Immunosuppressive Agents)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - FA2DM6879K (Vidarabine)
RN  - G1LN9045DK (Busulfan)
RN  - P2K93U8740 (fludarabine)
RN  - Q41OR9510P (Melphalan)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Agents, Alkylating/administration & dosage/therapeutic use
MH  - Busulfan/administration & dosage/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Cyclophosphamide/administration & dosage/therapeutic use
MH  - Cyclosporins/administration & dosage/therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Graft vs Host Disease/prevention & control
MH  - *Hematopoietic Stem Cell Transplantation/methods/mortality
MH  - Humans
MH  - Immunosuppressive Agents/administration & dosage/therapeutic use
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy
MH  - Leukemia, Myeloid, Acute/therapy
MH  - Male
MH  - Melphalan/administration & dosage/therapeutic use
MH  - Methotrexate/administration & dosage/therapeutic use
MH  - Middle Aged
MH  - Neural Tube Defects/therapy
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy
MH  - Time Factors
MH  - Vidarabine/administration & dosage/analogs & derivatives/therapeutic use
EDAT- 2002/07/05 10:00
MHDA- 2002/09/21 10:01
CRDT- 2002/07/05 10:00
PHST- 2002/07/05 10:00 [pubmed]
PHST- 2002/09/21 10:01 [medline]
PHST- 2002/07/05 10:00 [entrez]
PST - ppublish
SO  - Gac Med Mex. 2002 May-Jun;138(3):235-9.